Find an Eye MD near you!

Cellceutix Corporation announced that the U.S. FDA granted rare pediatric disease designation to kevetrin for the treatment of retinoblastoma.

Communicating with patients using cap color exclusively could lead to confusion and harm, especially when treating patients with more advanced disease.

A retrospective study found that a commonly prescribed drug for Parkinson’s, L-DOPA, may delay or prevent AMD.

This study adds to the growing body of literature that suggests natamycin may be more effective for treating fungal keratitis than voriconazole.

Ophthotech announced that Genentech will join Novartis and split rights to pegpleranib (Fovista) for the treatment of wet AMD.

Allergan announced that its biodegradable sustained-release bimatoprost implant is comparable to daily topical bimatoprost.